Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

McEachern

Showing results (421-430 of 494) with videos related to

Pageof 50
Sort By:
Molecular Genetics and Metabolism|May 19, 2007
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher diseaseKerry Anne McEachern, John Fung, Svetlana Komarnitsky, et al.
Nucleic Acids Research|April 13, 2024
Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivoSamantha L Sarli, Hassan H Fakih, Karen Kelly, et al.
Journal of Medicinal Chemistry|May 3, 2017
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain InhibitorYujun Zhao, Longchuan Bai, Liu Liu, et al.
Journal of Medicinal Chemistry|June 28, 2019
Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein InteractionAngelo Aguilar, Ke Zheng, Tianfeng Xu, et al.
Journal of Medicinal Chemistry|March 26, 2024
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate CancerZhixiang Chen, Mi Wang, Dimin Wu, et al.
Biological Psychiatry|January 2, 2020
Deletion of Glycogen Synthase Kinase-3β in D<sub>2</sub> Receptor-Positive Neurons Ameliorates Cognitive Impairment via NMDA Receptor-Dependent Synaptic PlasticityYan-Chun Li, Priyalakshmi Panikker, Bo Xing, et al.
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|December 6, 2024
Building a community of practice to address alcohol harms in Canada: Experience from the Canadian Alcohol Policy Evaluation projectTina R Price, Bryany Denning, Victoria Burns, et al.
Journal of Medicinal Chemistry|March 13, 2024
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor RegressionZhixiang Chen, Mi Wang, Dimin Wu, et al.
Plos Pathogens|November 6, 2009
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infectionKatharine N Bossart, Zhongyu Zhu, Deborah Middleton, et al.
Journal of Medicinal Chemistry|September 23, 2024
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC DegraderAtsunori Kaneshige, Yiqing Yang, Longchuan Bai, et al.
Pageof 50

Showing results (421-430 of 494) with videos related to

Sort By:
Pageof 50
Molecular Genetics and Metabolism|May 19, 2007
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher diseaseKerry Anne McEachern, John Fung, Svetlana Komarnitsky, et al.
Nucleic Acids Research|April 13, 2024
Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivoSamantha L Sarli, Hassan H Fakih, Karen Kelly, et al.
Journal of Medicinal Chemistry|May 3, 2017
Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain InhibitorYujun Zhao, Longchuan Bai, Liu Liu, et al.
Journal of Medicinal Chemistry|June 28, 2019
Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein InteractionAngelo Aguilar, Ke Zheng, Tianfeng Xu, et al.
Journal of Medicinal Chemistry|March 26, 2024
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate CancerZhixiang Chen, Mi Wang, Dimin Wu, et al.
Biological Psychiatry|January 2, 2020
Deletion of Glycogen Synthase Kinase-3β in D<sub>2</sub> Receptor-Positive Neurons Ameliorates Cognitive Impairment via NMDA Receptor-Dependent Synaptic PlasticityYan-Chun Li, Priyalakshmi Panikker, Bo Xing, et al.
Canadian Journal of Public Health = Revue Canadienne De Sante Publique|December 6, 2024
Building a community of practice to address alcohol harms in Canada: Experience from the Canadian Alcohol Policy Evaluation projectTina R Price, Bryany Denning, Victoria Burns, et al.
Journal of Medicinal Chemistry|March 13, 2024
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor RegressionZhixiang Chen, Mi Wang, Dimin Wu, et al.
Plos Pathogens|November 6, 2009
A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infectionKatharine N Bossart, Zhongyu Zhu, Deborah Middleton, et al.
Journal of Medicinal Chemistry|September 23, 2024
Discovery of AK-1690: A Potent and Highly Selective STAT6 PROTAC DegraderAtsunori Kaneshige, Yiqing Yang, Longchuan Bai, et al.
Pageof 50